Loading clinical trials...
Loading clinical trials...
A Double Blind, Placebo Controlled Two-part Study to Investigate the Dose-ranging Safety and Pharmacokinetics, Followed by the Efficacy and Safety of Cannabidiol (GWP42003-P) in Children and Young Adults With Dravet Syndrome
Conditions
Interventions
GWP42003-P 20 mg/kg/day Dose
Placebo control
Locations
22
United States
Miami, Florida, United States
Orlando, Florida, United States
Atlanta, Georgia, United States
Chicago, Illinois, United States
Iowa City, Iowa, United States
Boston, Massachusetts, United States
Start Date
March 30, 2015
Primary Completion Date
November 26, 2015
Completion Date
November 26, 2015
Last Updated
September 28, 2022
NCT02531880
NCT06097195
NCT06872125
NCT06315322
NCT06388707
NCT07505004
Lead Sponsor
Jazz Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions